Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue sarcomas. The experience of the EORTC soft tissue and bone sarcoma group

Sarcoma

Volumn 4, Issue 1-2, 2000, Pages 31-35

  Nielsen, Ole S ^a   Dombernowsky, Per ^b   Mouridsen, Henning ^c   Daugaard, Søren ^d   Van Glabbeke, Martine ^e   Kirkpatrick, Anne ^e   Verweij, Jaap ^f  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c FINSEN LABORATORY   (Denmark)

^d Rigshospitalet   (Denmark)

^e EORTC DATA CENTER   (Belgium)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIRUBICIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA;

EID: 0033929703     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1155/s1357714x00000062     Document Type: Article

References (23)

1. 1 Verweij J, Mouridsen HT, Nielsen OS, et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit Rev Oncoll Hematol 1995;20:193-201.
2. 2 Suit HD. Tumours of the connective and supporting tissues. Radioth Oncol 1995;34:93-104.
3. 3 O'Bryan RM, Luce JK, Talley RW. Phase II evaluation of adriamycin in human neoplasm. Cancer 1973;32:1-8.
4. 4 Borden EC, Amato DA, Rosenbaum CH. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987;5:840-50.
5. 5 Blackledge G, van Oosterom AT, Mouridsen HT, et al. Doxorubicin in relapsed soft tissue sarcoma: Justification of phase II evaluation of new drugs in this disease: An EORTC soft tissue and bone sarcoma group study. Em J Cancer Clin Oncol 1990;26:139-41.
6. 6 Suit HD, van Groeningen CJ, Mankin HJ, Rosenberg AE. Sarcoma of the soft tissues: In: Peckham M, Pinedo H, Veronesi U, eds. Oxford Textbook of Oncology. Oxford: Oxford University Press, 1995:1917-39.
7. 7 Bramwell VHC, Mouridsen HT, Mulder JH, et al. Carminomycin vs. adriamycin in advanced soft tissue sarcomas: an EORTC randomized phase II study. Eur J Cancer Clin Oncol 1983;19:1097-104.
8. 8 Bull FE, von Hoff DD, Balcerak SP, Stephens RL, Panettiere FJ. Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study. Cancer Treat Reports 1985;69:231-3.
9. 9 Launchbury AP, Habboubit N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treatm Rev 1993;19:197-228.
10. 10 Mouridsen HT, Bastholt L, Somers R, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer Clin Oncol 1987;23:1477-83.
11. 11 Nielsen OS, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 1998;78:1634-9.
12. 12 Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
13. 13 Peto R, Pike Mc, Armitage P, et al. Design and analysis of clinical trials requiring prolonged observation of each patient. Br J Cancer 1977;35:1-39.
14. 14 Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-8.
15. 15 Santoro A, Tursz T, Mouridsen HT, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the EORTC soft tissue and bone sarcoma group. J Clin Oncol 1995;13:1537-45.
16. 16 Chevalier B, Monteuquet PH, Fachini T, et al. Phase II study of epirubicin in advanced soft tissue sarcomas. Proc Am Soc Clin Oncol 1988;8:323.
17. 17 Jelic S, Vuletic L, Milanovic N, Tomasevic Z, Kovcin V. High-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Tumori 1990;76:467-71.
18. 18 Plosker GL, Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993;45:788-856.
19. 19 Garcia AA, Kempf RA, Rogers M, Muggia FM. A phase II study of Doxil (liposomal doxorubicin): Lack of activity in poor prognosis soft tissue sarcomas. Annals Oncol 1998;9:1131-3.
20. 20 Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998;16:1438-43.
21. 21 Palumbo R, Neumaier C, Cosso M, et al. Dose intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. Eur J Cancer 1999;35:66-72.
22. 22 Judson I, Radford J, Blay J-Y, et al. A randomised phase II trial of caelyx/doxil versus doxorubicin in advanced or metastatic soft tissue sarcomas (STS) - An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) trial. Proc of ASCO 1999;18:541a.
23. 23 Wexler LH. Ameliorating anthracycline cardiotoxicity in children with cancer: Clinical trials with dexrazoxane. Semin Oncol 1998;25(suppl 10):86-92.